---
title: How I treat iron overload in adult myelodysplastic syndrome
date: '2024-06-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38941618/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240629181447&v=2.18.0.post9+e462414
source: Blood
description: While clinical benefits of iron chelation therapy (ICT) in red blood
  cell transfusion dependent (RBC TD) hereditary anemias such as beta-thalassemia
  major are incontrovertible, the evidence supporting a similar benefit in patients
  with TD myelodysplastic neoplasms (MDS) and iron overload (IOL) is sometimes debated.
  MDS presents later in life, has a limited repertoire of life extending therapies,
  and patients may have comorbidities acting as competing causes of death. However,
  ...
disable_comments: true
---
While clinical benefits of iron chelation therapy (ICT) in red blood cell transfusion dependent (RBC TD) hereditary anemias such as beta-thalassemia major are incontrovertible, the evidence supporting a similar benefit in patients with TD myelodysplastic neoplasms (MDS) and iron overload (IOL) is sometimes debated. MDS presents later in life, has a limited repertoire of life extending therapies, and patients may have comorbidities acting as competing causes of death. However, ...